Loading...
Market
Will Element Biosciences secure additional funding or partnership deals by the end of 2024?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Company press releases, major financial news outlets
Story
Element Biosciences Raises $277 Million in Series D Venture Funding
Jul 12, 2024, 01:13 PM
Element Biosciences, a San Diego-based company specializing in next-generation sequencing (NGS), has successfully raised $277 million in a Series D venture funding round. The investment will enable the company to continue commercializing its AVITI benchtop genomic analyzer and launch its next product, AVITI24. This significant funding round positions Element Biosciences as a formidable competitor to Illumina in the DNA sequencing market. The company aims to leverage this capital to solidify its presence and drive rapid growth in the biotechnology sector.
View original story
Similar markets
Secures funding only • 25%
Secures partnership deal only • 25%
Secures both funding and partnership deal • 25%
Secures neither • 25%
No additional funding • 25%
Up to $10 million • 25%
$10 million to $50 million • 25%
Over $50 million • 25%